Stockscreener 앱 받기
37.07
3.92%
1.40
시간 외 거래:
37.07
전일 마감가:
$35.67
열려 있는:
$35.67
하루 거래량:
290.89K
Relative Volume:
0.69
시가총액:
$4.53B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+5.97%
1개월 성능:
+19.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$34.78
$37.98
1주일 범위
$34.78
$37.98
52주 변동 폭
$24.51
$37.98
Parabilis Medicines Inc Stock (PBLS) Company Profile
Compare PBLS vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PBLS
Parabilis Medicines Inc
|
37.07 | 4.58B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Parabilis Medicines Inc 주식(PBLS)의 최신 뉴스
Top Parabilis Medicines (PBLS) Competitors 2026 - marketbeat.com
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - moomoo.com
Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Parabilis Medicines (PBLS): ARCH Venture group discloses 6.4M-share, 5.3% ownership - Stock Titan
BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating - moomoo.com
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform (NASDAQ:PBLS) - Seeking Alpha
PBLS SWOT Analysis: Financial Resilience Amidst Clinical Challen - GuruFocus
Parabilis Medicines (PBLS) Earnings Date and Reports 2026 - MarketBeat
Parabilis Medicines: Q2 Earnings Snapshot - AOL.com
Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal - Stock Titan
Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - Kalkine
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Nigeria
PBLS: Lead asset zolucatetide shows strong efficacy and safety, driving a robust pipeline and growth - TradingView
Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell - marketscreener.com
Parabilis Medicines Reports Second Quarter 2026 Financial Results And Provides Business Updates - TradingView
Earnings Flash (PBLS) Parabilis Medicines, Inc. Reports Q2 Revenue $148,000 - marketscreener.com
Parabilis Medicines Advances Zolucatetide Toward Phase 3 in Desmoid Tumors, Announces Regeneron Collaboration and $1.1 Billion Cash Position - Quiver Quantitative
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - Yahoo Finance
Parabilis Medicines (NASDAQ:PBLS) Reaches New 1-Year HighWhat's Next? - marketbeat.com
Parabilis Medicines Ord Shs (PBLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Parabilis Medicines, Inc.Common Stock (Nasdaq:PBLS) Stock Quote - The Chronicle-Journal
Alphabet Reports Share Stake In SpaceX, Fervo Energy And Parabilis Medicines - TradingView
Parabilis Medicines (PBLS) Institutional Ownership 2026 - marketbeat.com
FMR LLC reports 10.3M-share position in Parabilis Medicines Inc (PBLS) - Stock Titan
Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Buy" by Analysts - marketbeat.com
PBLS|Parabilis Medicines Ord Shs|Price:31.820|Chg%:+0.540 - TradingKey
Alexis Borisy: Biotech Is Winning the Science and Losing the Story - finance.biggo.com
Parabilis Medicines, Inc. Revenue Breakdown – NASDAQ:PBLS - TradingView
Scribe secures $129M in a rare gene editing IPO - BioPharma Dive
Parabilis Medicines(PBLS.US) 10% Shareholder Buys US$6.92 Million in Common Stock - Moomoo
Form 4 Parabilis Medicines For: 22 July - Investing.com India
Form 4 Parabilis Medicines For: 22 July By Investing.com - Investing.com South Africa
Parabilis Medicines, Inc. (PBLS) Revenue (TTM) - Zacks Investment Research
RA Capital boosts stake in Parabilis Medicines (PBLS) with stock buys - Stock Titan
Parabilis Medicines (PBLS) 10K Form and Latest SEC Filings 2026 - MarketBeat
Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
LifeSci Capital Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $42 - Moomoo
With record listing prices, what the mid-year IPO market says about the current state of biopharma - The Pharma Letter
Primary Markets Group June 2026 U.S. IPO Update - Seeking Alpha
Parabilis Medicines, Inc. (NASDAQ:PBLS) Sees Significant Increase in Short Interest - MarketBeat
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart - mexc.co
Parabilis Medicines, Inc.'s Quiet Period Set To Expire on July 20th (NASDAQ:PBLS) - MarketBeat
Teresa Jurgensen Net Worth (2026) - GuruFocus
Thomas Rodolpho Kotarakos Net Worth (2026) - GuruFocus
Helen Huei In Ho Net Worth (2026) - GuruFocus
Soleus Capital Management, L.p. Net Worth (2026) - GuruFocus
Soleus Pe Gp Iii, Llc Net Worth (2026) - GuruFocus
Soleus Gp, Llc Net Worth (2026) - GuruFocus
PBLS Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Mohammed Fawzi Benzaghou Net Worth (2026) - GuruFocus
Parabilis Medicines Inc (PBLS) 재무 분석
Parabilis Medicines Inc (PBLS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):